ICUI
ICU Medical, Inc.
ICUI has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over ICUI overall, supported by stronger fundamentals and stronger valuation.
ICUI Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
ICUI's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
ICUI PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 19x | $177 | — |
| Cheap | 46x | $110 | -38% |
| Fair | 52x | $124 | -30% |
| Current | 74x | $177 | — |
| Expensive | 136x | $325 | +83% |
Historical ranges are pointers, not guarantees.
ICUI's PE is in its expensive range at 74x. If earnings grow as analysts expect, today's price would be 19x next year's earnings, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over ICUI in the historical PE scenario, which offers more potential upside but is not a forecast.
ICUI Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Growth | |
| Improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for ICUI, with profitability improving.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
ICUI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $9.19 | +283% |
| Q3 2026 | $2.40 | +$2.71 |
| Q2 2026 | $1.19 | +$2.71 |
| Q1 2026 | $1.86 | +$5.69 |
| Q4 2025 | $0.03 | +$4.86 |
| Q3 2025 | -$0.31 | +$4.26 |
| Q2 2025 | -$1.52 | +$1.40 |
| Q1 2025 | -$3.83 | -$1.38 |
| Q4 2024 | -$4.83 | -$3.60 |
ICUI has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
ICUI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $560.4M | +4.4% |
| Q2 2026 | $551.7M | +0.5% |
| Q1 2026 | $530.2M | -12% |
| Q4 2025 | $540.7M | -14% |
| Q3 2025 | $537M | -8.9% |
| Q2 2025 | $548.9M | -8% |
| Q1 2025 | $604.7M | +6.7% |
| Q4 2024 | $629.8M | +7.1% |
ICUI's revenue is down over the past year, though its latest quarter was up: $560M last quarter, up 4.4% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | +6.8 points |
| Q2 2026 | 7.1% | +5.2 points |
| Q1 2026 | 2.6% | +0.4 points |
| Q4 2025 | 1% | -4.9 points |
| Q3 2025 | 2.5% | +1.1 points |
| Q2 2025 | 1.9% | +0.6 points |
| Q1 2025 | 2.1% | +4 points |
| Q4 2024 | 6% | +8.1 points |
ICUI has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over ICUI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
ICUI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $83.4M | +202% |
| Q2 2026 | $61.6M | +$70.1M |
| Q1 2026 | $27.6M | -25% |
| Q4 2025 | $36M | +123% |
| Q3 2025 | $27.6M | +71% |
| Q2 2025 | -$8.5M | -114% |
| Q1 2025 | $36.7M | +23% |
| Q4 2024 | $16.1M | -74% |
ICUI generated $209M in free cash flow over the past year, up 190% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over ICUI on cash flow, with more consistent year-over-year improvement.
ICUI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.4% | +101K shares |
| 1 year | +1.9% | +459K shares |
| 3 years | +3.2% | +777K shares |
| 5 years | +16% | +3.4M shares |
| Available history | +17% | +3.6M shares |
ICUI has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
ICUI Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.7x | Moderate |
| Q2 2026 | 3.4x | Elevated |
| Q1 2026 | 4.1x | High |
| Q4 2025 | 4.0x | High |
| Q3 2025 | 3.7x | Elevated |
| Q2 2025 | 3.7x | Elevated |
| Q1 2025 | 4.5x | High |
| Q4 2024 | 4.9x | High |
ICUI's net debt is about 2.7 years of its operating earnings (EBITDA), down from 3.6 years a year ago.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over ICUI on leverage, with a lower net debt burden relative to earnings.
ICUI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 62.4 | Neutral |
| Stochastic | 49.5 | Neutral |
ICUI's weekly RSI is 62 (neutral) and its Stochastic is 49 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
ICUI PE vs Healthcare Sector
| Metric | ICUI | Sector median | Relative |
|---|---|---|---|
| PE | 74x | 26x | 186% above |
| PE % | 70 | 29 | 41 pts above |
ICUI is trading at 74x earnings, a 186% premium to the Healthcare sector's median of 26x.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over ICUI on valuation relative to its sector.
ICUI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $165.9 | 6.9% above |
| 20 week MA | $166.1 | 6.7% above |
| 50 week MA | $149.5 | 19% above |
| 100 week MA | $143.8 | 23% above |
| 200 week MA | $141.8 | 25% above |
ICUI is in an uptrend: it's above all five of its weekly moving averages, and 25% above its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR is in an uptrend: it's above all five of its weekly moving averages, and 106% above its 200-week average.
ICUI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $186.2 | $211.7 | +14% |
| 2021 | $211.7 | $235.7 | +11% |
| 2022 | $235.7 | $156.0 | -34% |
| 2023 | $156.0 | $99.7 | -36% |
| 2024 | $99.7 | $154.5 | +55% |
| 2025 | $154.5 | $147.9 | -4.3% |
| 2026 YTD | $147.9 | $177.3 | +20% |
ICUI has finished lower in three of the last six years. It's up 20% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over ICUI on returns for 2026, with the stronger performance.